Latest news
Iconovo develops new formulations to strengthen the product portfolio (only in Swedish)
Breddat erbjudande med egen utveckling.
Iconovo AB (publ) utökar erbjudandet med egenutvecklade läkemedelsformuleringar för bolagets inhalatorer. Ett…
Iconovo at CPhI in Madrid
Iconovo attended CPhI in Madrid last week which marked the start of our new collaboration with Stevanato Group and ICOcap. Truly an exiting moment and…
Press releases
Feb 08, 2023, 17:32
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 08, 2023, 17:31
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 17:31
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 03, 2023, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 03, 2023, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Jan 26, 2023, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Jan 26, 2023, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Jan 11, 2023, 08:40
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
